{
    "clinical_study": {
        "@rank": "92423", 
        "arm_group": {
            "arm_group_label": "RO5479599", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label dose-escalation study with an extension phase will evaluate the\n      safety and pharmacokinetics of RO5479599 in combination with Perjeta (pertuzumab) and\n      paclitaxel in patients with metastatic breast cancer expressing HER3 & HER2 protein. Cohorts\n      of patients will receive escalating doses of RO5479599 intravenously (i.v.) every three\n      weeks in combination with Perjeta 840 mg i.v. initial dose followed by 420 mg i.v. every\n      three weeks and paclitaxel 80 mg/m2 i.v. weekly. Anticipated time on study treatment is\n      until disease progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "A Study to Evaluate RO5479599 in Combination With Perjeta (Pertuzumab) and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically confirmed metastatic breast cancer expressing HER3 & HER2 protein\n\n          -  Patients must be willing to undergo a fresh (pretreatment) tumor/metastases biopsy\n             that will be used to assess the level of HER3 protein expression by IHC and central\n             pathology review\n\n          -  HER2 status confirmed on same tumor/metastases by a central laboratory. BC tumors\n             and/or metastases must be HER2 IHC 1+/ISH- or HER2 ICH 2+/ISH- as assessed by\n             parallel testing of protein and gene amplification using an FDA-approved test\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n\n          -  Taxane-naive patients or patients who have received taxanes as part of an\n             adjuvant/neoadjuvant treatment regimen with a disease-free interval of at least 1\n             year. Patients who have received a docetaxel-containing regimen in the metastatic\n             setting may be eligible. Patients who have received paclitaxel/nab-paclitaxel in the\n             metastatic setting but have discontinued paclitaxel/nab-paclitaxel for a reason other\n             than disease progression and have had a taxane-free interval of at least 6 months may\n             be eligible\n\n          -  Radiologically measurable or clinically evaluable disease according to RECIST\n             criteria\n\n          -  Last dose of systemic anti-neoplastic therapy > 21 days prior to first study\n             treatment infusion. Palliative radiotherapy is allowed up to 2 weeks before the first\n             study treatment infusion\n\n          -  All acute toxic effects of any prior radiotherapy, chemotherapy or surgical procedure\n             must have resolved to Grade </= 1, except alopecia (any grade)\n\n          -  Adequate hematological, liver and renal function\n\n          -  Baseline left ventricular ejection fraction (LVEF) of >/= 50% (measured by\n             echocardiography)\n\n          -  Female patients of childbearing potential and male patients must agree to use\n             effective contraception as defined by protocol during the study and for at least 6\n             months after the last dose of study medication\n\n          -  Patients with Gilbert's Syndrome will be eligible for the study\n\n        Exclusion Criteria:\n\n          -  History of clinical evidence of central nervous system (CNS) primary tumors or\n             metastases including leptomeningeal metastases unless they have been previously\n             treated, are asymptomatic and have had no requirement for steroids or enzyme-inducing\n             anti-convulsants in the last 14 days\n\n          -  Evidence of significant, uncontrolled concomitant diseases which could affect\n             compliance with the protocol or interpretation of results, including uncontrolled\n             diabetes mellitus\n\n          -  Active or uncontrolled infections\n\n          -  Known human immunodeficiency virus (HIV) or known active hepatitis B virus (HBV) or\n             hepatitis C virus (HCV) infection\n\n          -  Major surgery or significant traumatic injury < 28 days prior to 1st study treatment\n             infusion (excluding biopsies) or anticipation of the need for a major surgery during\n             study treatment\n\n          -  Pregnant or breast-feeding women\n\n          -  Known hypersensibility to any of the components of RO5479599, pertuzumab or\n             paclitaxel\n\n          -  Patients with contraindications for paclitaxel therapy according to the SmPC\n\n          -  Therapy with an antibody or immunotherapy concurrently or within a period of time\n             where drug exposure is still considered biologically active (usually < 5x t1/2) prior\n             to first dose of study treatment\n\n          -  Regular immunosuppressive therapy (i.e., for organ transplantation, chronic\n             rheumatologic disease)\n\n          -  Concurrent high doses of systemic corticosteroids (> 20 mg of dexamethasone a day of\n             equivalent for > 7 consecutive days)\n\n          -  Baseline QTc interval of > 470 ms, patients with baseline resting bradycardia < 45\n             beats per minute or baseline resting tachycardia > 100 beats per minute\n\n          -  Uncontrolled hypertension, unstable angina, congestive heart failure of any New York\n             Heart Association (NYHA) classification, serious cardiac arrhythmia requiring\n             treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia),\n             history of myocardial infraction within 6 months of enrollment or symptomatic LVEF\n             dysfunction\n\n          -  A history of grade >/= 3 peripheral neuropathy of any etiology"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918254", 
            "org_study_id": "BP28752", 
            "secondary_id": "2013-000090-67"
        }, 
        "intervention": [
            {
                "arm_group_label": "RO5479599", 
                "description": "Multiple escalating doses", 
                "intervention_name": "RO5479599", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RO5479599", 
                "description": "840 mg i.v. initial dose followed by 420 mg i.v. every 3 weeks", 
                "intervention_name": "pertuzumab [Perjeta]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RO5479599", 
                "description": "80 mg/m2 i.v. weekly", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8benhavn", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45122"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "France", 
                "Germany", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE IB, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF RO5479599, A GLYCOENGINEERED ANTIBODY AGAINST HER3, ADMINISTERED IN COMBINATION WITH PERTUZUMAB AND PACLITAXEL IN PATIENTS WITH METASTATIC BREAST CANCER EXPRESSING HER3 &HER2 PROTEIN", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BP28752 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Incidence of dose-limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Incidence and severity of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Incidence of anti-RO5479599 antibodies (HAHAs)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918254"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Pharmacodynamics: Blood/serum markers", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}